Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents
| Autor: | Hiroshi Fukui, Chie Morioka, Masahisa Toyohara, Ryuichi Noguchi, Hideto Kawaratani, Junichi Yamao, Yusaku Shirai, Kosuke Kaji, Masao Fujimoto, Hitoshi Yoshiji, Masahito Uemura, Tatsuhiro Tsujimoto, Akira Mitoro, Motoyuki Yoshida, Yosuke Aihara, Yasuhide Ikenaka, Masayoshi Sawai |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Predictive marker business.industry Cancer Articles Bioinformatics medicine.disease Molecular medicine Vascular endothelial growth factor Regimen chemistry.chemical_compound chemistry Internal medicine Hepatocellular carcinoma Menatetrenone medicine Perindopril business medicine.drug |
| Zdroj: | Oncology Letters. 2:69-73 |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2010.196 |
| Popis: | The identification of biomarkers of anti-angiogenic therapy that predict clinical benefit is of vital importance. We previously reported that a combination treatment with clinically available safe agents, specifically angiotensin-converting enzyme inhibitor (ACE-I) and vitamin K (VK), inhibited the cumulative recurrence of hepatocellular carcinoma (HCC) via suppression of the vascular endothelial growth factor (VEGF). The present study aimed to identify non-invasive biological markers that predict the clinically beneficial effect of this combination regimen. A combination of ACE-I (perindopril; 4 mg/day) and VK (menatetrenone; 45 mg/day) was administered for 54 months following curative therapy for HCC. The cumulative recurrence and several indices, which are reportedly considered as biological markers of anti-angiogenic therapies, were analyzed. The combined treatment of ACE-I and VK markedly inhibited the cumulative recurrence of HCC during the 54-month follow-up. The serum VEGF and soluble VEGF receptor (sVEGFR)-2 were significantly suppressed with this combination regimen, whereas sVEGFR-1 was not. In HCC patients without recurrence, a significant suppression of VEGF and sVEGFR-2 was achieved within 6 and 3 months after treatment, respectively. In conclusion, the combination treatment of ACE-I and VK is a potentially novel anti-angiogenic strategy for secondary chemoprevention against HCC since the two agents are widely used in clinical practice without serious side effects. Furthermore, sVEGFR-2 may become a useful clinical predictive marker of this combination treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|